{"product_id":"amgen-bcg-matrix","title":"Amgen Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the strategic potential of Amgen's product portfolio with a clear understanding of its BCG Matrix. See which products are driving growth as Stars, generating stable revenue as Cash Cows, requiring careful consideration as Question Marks, or potentially needing divestment as Dogs.\u003c\/p\u003e\n\u003cp\u003eThis glimpse into Amgen's strategic positioning is just the beginning. Purchase the full BCG Matrix report for a comprehensive breakdown of each product's quadrant placement, along with actionable insights and data-driven recommendations to optimize your investment and product development strategies.\u003c\/p\u003e\n\u003cp\u003eDon't miss out on the opportunity to gain a competitive edge. Invest in the complete Amgen BCG Matrix and equip yourself with the knowledge to make informed decisions for future success.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTezspire (tezepelumab-ekko)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTezspire (tezepelumab-ekko) is a significant growth engine for Amgen, demonstrating robust sales momentum and broadening its therapeutic reach beyond severe asthma. Its unique position as the first biologic for severe asthma without phenotype or biomarker restrictions unlocks substantial market potential.\u003c\/p\u003e\n\u003cp\u003eAmgen and AstraZeneca are actively pursuing expanded indications for Tezspire, with promising Phase 3 data emerging for its use in Chronic Obstructive Pulmonary Disease (COPD) and chronic rhinosinusitis with nasal polyps. These developments are poised to further solidify Tezspire's position as a key player in respiratory medicine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRepatha (evolocumab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRepatha, a key PCSK9 inhibitor from Amgen, demonstrates robust sales expansion, fueled by rising patient uptake and physician confidence, even with some pricing adjustments.  In 2023, Repatha achieved over $2 billion in global sales, solidifying its market leadership in cholesterol management.\u003c\/p\u003e\n\u003cp\u003eThe drug has successfully treated millions worldwide, offering a vital treatment option for lowering LDL cholesterol. Amgen's commitment to Repatha is further underscored by an ongoing Phase 4 trial investigating its potential to reduce cardiovascular events following a heart attack, a significant area of unmet medical need.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvenity (romosozumab-aqqg)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEvenity, a significant osteoporosis treatment from Amgen, is showing impressive sales momentum.  In 2023, its net sales reached $776 million, marking a substantial increase from the previous year, driven by strong demand. \u003c\/p\u003e\n\u003cp\u003eThe drug's robust year-over-year sales growth, particularly in the United States, is a key indicator of its success. This growth is largely attributed to increasing prescriber adoption, especially among patients identified as high-risk for osteoporosis, highlighting its perceived clinical value. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBlincyto (blinatumomab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBlincyto, a groundbreaking bispecific T-cell engager, has demonstrated robust, consistent double-digit sales growth. This impressive performance is largely attributed to its widespread adoption and prescribing for B-cell precursor acute lymphoblastic leukemia (ALL).\u003c\/p\u003e\n\u003cp\u003eAmgen is actively pursuing further development for Blincyto, notably advancing its subcutaneous administration, which promises enhanced patient convenience. Furthermore, the company is exploring its therapeutic potential beyond oncology, investigating its efficacy in autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eSales Growth:\u003c\/strong\u003e Blincyto has achieved consistent double-digit sales growth.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePrimary Indication:\u003c\/strong\u003e Broad prescribing in B-cell precursor acute lymphoblastic leukemia.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDevelopment Pipeline:\u003c\/strong\u003e Advancing subcutaneous administration for improved patient experience.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNew Therapeutic Areas:\u003c\/strong\u003e Exploring potential in rheumatoid arthritis and systemic lupus erythematosus.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImdelltra (tarlatamab-dlle)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImdelltra (tarlatamab-dlle), a recent addition to Amgen's portfolio, is positioned as a potential star in the BCG matrix. It gained accelerated FDA approval in May 2024 for extensive-stage small cell lung cancer (ES-SCLC), a challenging area with significant unmet need.\u003c\/p\u003e\n\u003cp\u003eInitial sales performance for Imdelltra has been robust, indicating strong market acceptance. This early success is further bolstered by the positive results from its Phase 3 confirmatory study, which demonstrated a statistically significant improvement in overall survival for patients treated with tarlatamab.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct:\u003c\/strong\u003e Imdelltra (tarlatamab-dlle)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIndication:\u003c\/strong\u003e Extensive-stage small cell lung cancer (ES-SCLC)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eApproval Status:\u003c\/strong\u003e Accelerated FDA Approval (May 2024)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKey Data:\u003c\/strong\u003e Phase 3 study showed improved overall survival, supporting its potential as a blockbuster drug.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImdelltra's Rapid Rise: A Lung Cancer Breakthrough\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImdelltra, approved in May 2024 for extensive-stage small cell lung cancer, shows early promise as a star product for Amgen. Its accelerated FDA approval was based on a Phase 3 study demonstrating improved overall survival, a critical metric in this challenging indication. The initial market uptake suggests strong physician confidence and a significant unmet need being addressed.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eApproval Date\u003c\/th\u003e\n\u003cth\u003eKey Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eImdelltra (tarlatamab-dlle)\u003c\/td\u003e\n\u003ctd\u003eExtensive-stage small cell lung cancer (ES-SCLC)\u003c\/td\u003e\n\u003ctd\u003eMay 2024\u003c\/td\u003e\n\u003ctd\u003ePhase 3: Improved overall survival\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThis BCG Matrix overview provides strategic insights into Amgen's product portfolio, highlighting which units to invest in, hold, or divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAmgen's BCG Matrix provides a clear, visual snapshot of its portfolio, easing the pain of resource allocation decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProlia (denosumab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProlia stands as a significant cash cow for Amgen, consistently delivering robust revenue. In 2023, Prolia achieved $3.27 billion in sales, a testament to its strong market presence in osteoporosis treatment.\u003c\/p\u003e\n\u003cp\u003eDespite being a mature product, Prolia's established efficacy and widespread adoption continue to fuel substantial cash flow for Amgen. The drug's consistent volume growth underscores its enduring demand.\u003c\/p\u003e\n\u003cp\u003eHowever, the landscape is shifting, with biosimilar competition anticipated to begin impacting Prolia's sales in the latter half of 2025, posing a future challenge to its cash cow status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXgeva (denosumab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXgeva, a key product for Amgen, is a significant revenue generator, particularly for managing bone metastases in cancer patients.  Its strong market presence, however, is expected to face pressure from biosimilar entrants, with notable impacts anticipated from late 2025 onwards.\u003c\/p\u003e\n\u003cp\u003eIn the first quarter of 2024, Amgen reported Xgeva sales of $569 million, showcasing its continued importance to the company's portfolio. While this indicates robust performance, the looming biosimilar threat, especially as patent expirations approach, positions it as a potential future challenge within the BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnbrel (etanercept)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnbrel, a cornerstone in Amgen's portfolio for autoimmune diseases, continues to be a significant revenue generator, acting as a classic cash cow. Despite facing increasing competition and a noticeable decline in sales, its substantial patient base and established market presence still contribute robust cash flows to the company. For instance, in the first quarter of 2024, Enbrel's sales were reported at $496 million, a decrease from the previous year, highlighting the competitive landscape but also its enduring revenue-generating capacity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTepezza (teprotumumab-trbw)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTepezza, now part of Amgen's portfolio following the Horizon Therapeutics acquisition, is a significant revenue contributor, particularly within the rare disease segment.\u003c\/p\u003e\n\u003cp\u003eThis drug, a first-in-class treatment for Graves' ophthalmopathy, addresses a critical unmet medical need, solidifying its position as a valuable cash-generating asset for Amgen.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eTepezza's Revenue Impact:\u003c\/strong\u003e In the first quarter of 2024, Tepezza generated $529 million in net sales, underscoring its substantial contribution to Amgen's overall revenue.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Position:\u003c\/strong\u003e As the only FDA-approved therapy for moderate to severe Graves' ophthalmopathy, Tepezza holds a dominant market position.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGrowth Potential:\u003c\/strong\u003e Despite some sales variability, Tepezza's unique therapeutic offering and the ongoing need for effective treatments suggest continued strong performance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKrystexxa (pegloticase)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKrystexxa, acquired through the Horizon Therapeutics deal, is a significant revenue generator for Amgen.  This treatment targets chronic refractory gout, a condition with limited therapeutic options, establishing it as a reliable income source.\u003c\/p\u003e\n\u003cp\u003eThe drug's effectiveness in addressing a specific unmet medical need solidifies its position.  In 2023, Amgen reported Krystexxa sales of approximately $577 million, demonstrating its robust contribution to the company's financial performance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eKrystexxa's Role:\u003c\/strong\u003e A key product from the Horizon acquisition, bolstering Amgen's revenue.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Niche:\u003c\/strong\u003e Addresses chronic refractory gout, a specific unmet medical need.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinancial Impact:\u003c\/strong\u003e Generated around $577 million in sales in 2023, highlighting its value.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBCG Matrix Classification:\u003c\/strong\u003e Positioned as a Cash Cow due to its strong market share and low growth potential in a niche indication.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Products: The Financial Backbone\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen's portfolio includes several established products that function as cash cows, generating consistent revenue with mature market positions. These products, while not experiencing rapid growth, provide a stable financial foundation for the company.\u003c\/p\u003e\n\u003cp\u003eProlia and Xgeva, both significant revenue drivers, are key examples of Amgen's cash cows, though they face future challenges from biosimilar competition. Enbrel, despite market pressures, continues to contribute substantially.\u003c\/p\u003e\n\u003cp\u003eTepezza and Krystexxa, acquired through the Horizon Therapeutics deal, have quickly established themselves as valuable cash cows by addressing specific unmet medical needs in rare disease segments.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2023 Sales (Approx.)\u003c\/th\u003e\n\u003cth\u003eQ1 2024 Sales\u003c\/th\u003e\n\u003cth\u003eBCG Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProlia\u003c\/td\u003e\n\u003ctd\u003e$3.27 billion\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXgeva\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e$569 million\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnbrel\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e$496 million\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTepezza\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e$529 million\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKrystexxa\u003c\/td\u003e\n\u003ctd\u003e$577 million\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eAmgen BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe Amgen BCG Matrix preview you're seeing is the identical, fully formatted document you will receive immediately after purchase. This means no watermarks or placeholder content, just a professionally crafted strategic tool ready for your analysis and decision-making. You can confidently use this preview to understand the depth and clarity of the insights provided, knowing the purchased version will be exactly the same, enabling you to seamlessly integrate it into your business planning and presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610814300537,"sku":"amgen-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/amgen-bcg-matrix.png?v=1754746661","url":"https:\/\/growthsharematrix.com\/products\/amgen-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}